Fruquintinib

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA. Results from the SACHI China Phase III study of savolitinib in combination with osimertinib in patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR inhibitor therapy will be presented at a late breaking oral presentation. SACHI had met the pre-defined primary endpoint of progression-free survival (PFS) in a planned interim analysis. SACHI data supports the New Drug Application (NDA) for this oral-only treatment, which has been accepted and granted priority review in China. Further data with additional analysis stratified by brain metastasis status from a high MET overexpression and/or amplification treatment subset of the SAVANNAH Phase II study of the savolitinib and osimertinib combination in NSCLC patients harboring EGFR mutation and MET amplification or overexpression after progressing on osimertinib were reported. The savolitinib and osimertinib combination demonstrated better efficacy outcomes compared to savolitinib plus placebo. The combination showed promising central nervous system (“CNS”) activity, with reduced CNS progression and fewer new CNS lesions. Results will be presented from the dose-escalation stage of the Phase I study of ranosidenib (HMPL-306), a novel, small-molecule, highly selective oral dual-inhibitor of both Isocitrate dehydrogenase (“IDH”) 1 and IDH2 enzymes, being studied in patients with locally advanced or metastatic solid tumors with IDH mutations. Results show that the compound was well tolerated, showing target inhibition and durable responses in patients. Efficacy signals were observed especially in the efficacy evaluated group of lower-grade glioma patients (N=14), with an objective response rate (“ORR”) of 7.1% and a disease control rate (“DCR”) of 100%. Results will also be presented from the sub-group analyses of the FRUSICA-1 open-label, single-arm, pivotal Phase II study to evaluate the efficacy and safety of fruquintinib plus sintilimab in previously treated advanced endometrial cancer (EMC) patients with pMMR (proficient mismatch repair) status. Efficacy findings for patients with serous carcinoma (N=27) were clinically meaningful and characterized by responses similar to those observed in full trial population (N=98), with an Independent Review Committee (“IRC”)-assessed ORR of 37.0% and a DCR of 88.9%. The analysis of whether the response was affected by prior neoadjuvant/adjuvant chemotherapy (“NACT/ACT”) showed durable and clinically meaningful responses regardless of whether the patient had received NACT/ACT. Results were comparable for patients with and without prior NACT/ACT, with an IRC-assessed ORR of 34.0% versus 31.4% and DCR of 85.1% versus 82.4%, respectively. Results from two subgroup analyses of a Phase IV study of fruquintinib involving 2,798 colorectal cancer patients in China will be presented. In the subgroup analysis evaluating the safety of fruquintinib as monotherapy and in combination therapy, fruquintinib demonstrated a manageable safety profile in both groups. Treatment-emergent adverse events (TEAE) of Grade 3 or above occurred in 23.94% in the fruquintinib monotherapy group and 26.06% in the combination therapy group with other anti-cancer treatments. The most common treatment related adverse events (TRAE) of any grade in both groups were palmar-plantar erythrodysesthesia (PPES) and hypertension. The combination therapy group exhibited a longer treatment duration, potentially indicating improved patient outcomes. In the subgroup analysis by age, the safety of fruquintinib was assessed in younger (age <50) and late-elderly (age ≥75) patients. The safety profile was comparable across both age groups, with younger patients receiving more intensive treatment. Combination therapy with fruquintinib also showed a longer duration than monotherapy in both age subgroups, which may suggest improved survival potential. Details of the presentations, including links to available abstracts, are as follows: Abstract title Presenter / Lead author Presentation details SPONSORED STUDIES Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China LBA8505 Oral Abstract Session: Lung Cancer - Non-Small Cell Metastatic Sunday, June 1, 2025 9:48 AM CDT Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO) Benjamin Philip Levy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 8513 Rapid Oral Session: Lung Cancer - Non-Small Cell Metastatic Monday, June 2, 2025 8:06 AM CDT Phase I study of HMPL-306, an inhibitor of mutant IDH1/IDH2 (mIDH1/2), in western patients (pts) with advanced mIDH solid tumor, including glioma Jordi Rodon Ahnert, The University of Texas MD Anderson Cancer Center, Houston, TX 2013 Rapid Oral Session: Central Nervous System Tumors Saturday, May 31, 2025 3:06 PM CDT Analysis of serous carcinoma subgroup in FRUSICA-1: Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with pMMR status Xiaohua Wu, Fudan University Shanghai Cancer Center, Shanghai, China 5596 Poster Session: Gynecologic Cancer The Impact of Prior Neoadjuvant/Adjuvant Chemotherapy (NACT/ACT) on Fruquintinib Plus Sintilimab Outcomes in Advanced Endometrial Cancer (EMC) Patients with pMMR Status: A Subgroup Analysis of FRUSICA-1 Jing Wang, Hunan Cancer Hospital, Changsha, China 5611 Poster Session: Gynecologic Cancer Safety of fruquintinib in young and late-elderly Chinese patients with colorectal cancer in real-world clinical practice: Age subgroup analysis of a fruquintinib Phase IV study Yi Wang, Ningbo No.2 Hospital, Ningbo, China e15512 Publication Only: Gastrointestinal Cancer - Colorectal and Anal Safety of fruquintinib monotherapy and combination therapy in Chinese Patients with colorectal cancer in real-world clinical practice: A subgroup analysis from Phase IV study Zhiqiang Wang, Sun Yat-Sen University Cancer Center, Guangzhou, China e15515 Publication Only: Gastrointestinal Cancer - Colorectal and Anal The appropriate therapeutic sequence with angiogenesis inhibitor and chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Exploratory analysis from the Phase III FRUTIGA study Jin Li, Shanghai East Hospital, Tongji University, Shanghai, China e16011 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Subgroup analysis of efficacy and safety of fruquintinib plus paclitaxel versus paclitaxel in gastroesophageal junction adenocarcinoma patients from FRUTIGA: A randomized Phase III clinical trial in second-line treatment of gastric/gastroesophageal junction Tianshu Liu, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China e16012 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary INVESTIGATOR-INITIATED STUDIES Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): a single-arm, Phase II study Yanhong Gu, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China 4042 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Updated results of fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): a single-arm, open-label Phase II study Chenchen Wang, Fudan University Shanghai Cancer Center, Shanghai, China 4046 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Open-label, single-arm, single-center Phase Ib/II clinical study of fruquintinib combined with trastuzumab and XELOX in the first-line treatment of advanced HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma Huifang Lv, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China TPS4203 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary A multi-cohort real-world study of treatment for metastatic colorectal cancer (mCRC): Overall efficacy analysis and subgroup analysis of previous bevacizumab use or not Wangxia Lv, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China e15530 Publication Only: Gastrointestinal Cancer - Colorectal and Anal Real-world Observational Study of Fruquintinib in Combination with Irinotecan and Capecitabine as Second-line Treatment in Patients with Advanced Colorectal Cancer Ling Xu, the First Hospital of China Medical University, Shenyang, China e15539 Publication Only: Gastrointestinal Cancer - Colorectal and Anal Preliminary results of fruquintinib in combination with FOLFIRI as second-line treatment for RAS-mutant metastatic colorectal cancer: a prospective single-center Phase II study Ru Jia, Fifth Medical Center, Chinese PLA General Hospital, Beijing, China e15541 Publication Only: Gastrointestinal Cancer - Colorectal and Anal Evaluating the efficacy of fruquintinib versus regorafenib and trifluridine/tipiracil in treating advanced metastatic colorectal cancer: A match-adjusted indirect comparison Shukui Qin, Gastrointestinal Cancer Center of Nanjing Tianyinshan Hospital, China Pharmaceutical University, Nanjing, China e15550 Publication Only: Gastrointestinal Cancer - Colorectal and Anal Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated response and surgical results from a single-arm, Phase II clinical trial Fei Ma, Henan Cancer Hospital, Zhengzhou, China e16016 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary A Phase II study to evaluate the efficacy and safety of fruquintinib combined with envafolimab in patients with advanced or unresectable locally advanced osteosarcoma and soft tissue sarcoma Chenliang Zhou, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China e23506 Publication Only: Sarcoma Efficacy and safety of surufatinib (Sur) plus paclitaxel (Pac) as second line (2L) treatment for advanced gastric cancer (aGC): Final results from a Phase II trial Xiuying Xiao, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 4028 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Efficacy and safety of surufatinib (S) plus KN046 (K) and chemotherapy in first line (1L) advanced pancreatic cancer (PC): a single-arm, Phase Ib/II trial Wenquan Wang, Zhongshan Hospital, Fudan University, Shanghai, China 4157 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary First-Line Treatment with Surufatinib, Camrelizumab, Nab-paclitaxel, and S-1 in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): A Phase Ib/II Randomized Study Ru Jia/ Guanghai Dai, the Fifth Medical Center of the PLA General Hospital, Beijing, China 4161 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary A prospective, single-arm, Phase II trial exploring the use of pamiparib combined with surufatinib as neoadiuvant therapy for advanced, unresectable ovarian cancer (PASSION) Bairong Xia, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China 5589 Poster Session: Gynecologic Cancer The efficacy and safety of Surufatinib monotherapy as a third-line treatment for advanced hepatocellular carcinoma: A single-arm, open-label, multi-center Phase II study Fuxiang Zhou, Zhongnan Hospital of Wuhan University, Wuhan, China e16209 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Surufatinib combined with gemcitabine and cisplatin and immune checkpoint inhibitor (ICI) for unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma Jingtao Zhang/ Xuetao Shi, Cancer Hospital of Shandong First Medical University, Jinan, China e16222 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Updated results from a multicenter, single-arm Phase II study of surufatinib plus sintilimab and lBl310 in patients with high-grade advanced neuroendocrine neoplasm (HG-NEN) Ming Lu/ Lin Shen, Peking University Cancer Hospital, Beijing, China e16342 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary A prospective, single-arm, Phase II study of surufatinib in combination with gemcitabine and nab-paclitaxel for the neoadjuvant treatment of resectable and borderline resectable pancreatic cancer Song Gao/ Jihui Hao, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China e16442 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary About HUTCHMED HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of savolitinib, ranosidenib, fruquintinib and surufatinib, the further clinical development for savolitinib, ranosidenib, fruquintinib and surufatinib, its expectations as to whether any studies on savolitinib, ranosidenib, fruquintinib and surufatinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of savolitinib, ranosidenib, fruquintinib and surufatinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of savolitinib, ranosidenib, fruquintinib and surufatinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. CONTACTS Investor Enquiries +852 2121 8200 / ir@hutch-med.com Media Enquiries FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com Panmure Liberum Nominated Advisor and Joint Broker Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500 HSBC Joint Broker Simon Alexander / Alina Vaskina / Arnav Kapoor +44 20 7991 8888 Cavendish Joint Broker Geoff Nash / Nigel Birks +44 20 7220 0500 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

SEQUOIA研究的新数据将通过两场口头报告展示，凸显百悦泽®用于慢性淋巴细胞白血病（CLL）患者的一线治疗取得获益当前管线产品的早期阶段数据，显现出其用于治疗包括乳腺癌在内的多种实体肿瘤的实力前景数据进一步凸显百泽安®作为独特设计的PD-1抑制剂的有效性及安全性特征美国加州圣卡洛斯——百济神州有限公司（纳斯达克代码：ONC；香港联交所代码：06160；上交所代码：688235）是一家全球肿瘤治疗创新公司，今日宣布将于2025年5月30日至6月3日在伊利诺伊州芝加哥举行的美国临床肿瘤学会（ASCO）年会上分享23篇摘要，主要包括公司产品组合在血液和实体肿瘤治疗方面获得的新数据。两篇摘要被选为进行快速口头报告。这些数据也展现出公司以多种方式应对癌症，并为全球尽可能多的患者提供创新药物的愿景。ASCO是推动癌症治疗进步的强有力平台。我们很荣幸有23篇摘要被大会接受，这也展现出我们致力于改善全球更多患者治疗效果的使命。我们今年的展示包含百悦泽®用于治疗CLL患者的长期随访结果，以及两款极具前景乳腺癌在研药物的首批临床数据，这充分展现出我们肿瘤治疗产品所具有的深度与潜能，以及我们始终致力于为多种类型的癌症提供具有变革意义的药物的承诺。演示展示了百悦泽®（泽布替尼）在面向广泛患者群体时所取得的令人印象深刻的临床特征，其中亮点包括：SEQUOIA研究C组患者的长期随访数据，对百悦泽®用于治疗初治（TN）伴有del（17p）突变的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者进行了评估SEQUOIA研究D组全部人群的首次数据读出，对百悦泽®联合维奈克拉用于治疗伴有或未伴有del （17p）和/或TP53的TN CLL/SLL患者进行了评估通过对临床试验和真实世界证据的稳健分析，加深了对CLL和套细胞淋巴瘤（MCL）治疗模式、安全性和治疗结果的理解基于网络荟萃分析（Network Meta-Analysis, NMA）获得的百悦泽®对比固定疗程方案有效性比较数据，以及在不同患者群体中评估BTK抑制剂使用、治疗差异，以及临床结果的真实世界研究早期阶段数据包含首次亮相的百济神州乳腺癌新管线产品临床数据，其中亮点包括：BG-C9074（B7-H4 ADC，靶向B7-H4蛋白的拓扑异构酶抑制剂抗体偶联药物）用于治疗晚期实体瘤患者（包括乳腺癌患者）的剂量递增研究初步结果BG-68501（CDK2i，一种细胞周期蛋白依赖性激酶2抑制剂）在用于治疗既往接受过CDK4/6抑制剂治疗的HR+/HER2-乳腺癌患者时展现出的早期临床活性，支持对其进行开发作为CDK2依赖性肿瘤治疗的下一线选择RATIONALE-213研究最终分析结果表明，经PET引导的百泽安®联合新辅助化疗/放疗用于治疗可切除食管鳞状细胞癌（ESCC）患者（无论术前化疗是否为患者带来缓解）展现出极具前景的有效性和良好的安全性特征。这进一步证明该款PD-1抑制剂能带来具有临床意义的有效性获益和一致的安全性特征。百济神州在2025年ASCO年会期间的展示血液肿瘤百悦泽®摘要标题：SEQUOIA研究C组5年随访：泽布替尼作为单药用于伴有del（17p）初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的一线治疗报告详情（美国中部夏令时间）：快速口头报告：7011报告标题：血液恶性肿瘤 - 淋巴瘤及慢性淋巴细胞白血病报告日期/时间：2025年5月31日上午8:00-9:30主要作者：C.S. Tam摘要标题：泽布替尼联合维奈克拉用于治疗初治CLL/SLL患者：SEQUOIA研究D组结果报告详情（美国中部夏令时间）：快速口头报告：7009报告标题：血液恶性肿瘤 - 淋巴瘤及慢性淋巴细胞白血病报告日期/时间：2025年5月31日上午8:00-9:30主要作者：M. Shadman实体肿瘤百泽安®摘要标题：经正电子发射断层扫描引导的替雷利珠单抗（BGB-A317）联合新辅助化疗/放化疗用于治疗可切除食管鳞状细胞癌患者：RATIONALE-213最终分析报告详情（美国中部夏令时间）：海报编号：317展示标题：胃肠道癌症 - 胃食管、胰腺和肝胆展示日期/时间：2025年5月31日上午9:00至中午12:00主要作者：L. Chen摘要标题：评估替雷利珠单抗联合呋喹替尼用于治疗特定实体瘤患者有效性和安全性的多中心、开放性、2期研究最终分析报告详情（美国中部夏令时间）：海报编号：251展示标题：发展治疗 - 免疫疗法展示日期/时间：2025年6月2日下午1:30-4:30主要作者：K. Lee管线产品BG-68501（CDK2抑制剂）摘要标题：一款选择性CDK2抑制剂BG-68501作为单药或联合氟维司群用于HR+/HER2-乳腺癌患者以及其他晚期实体肿瘤患者治疗的首次人体1a/b期剂量递增/扩展研究：首次披露临床数据报告详情（美国中部夏令时间）：海报编号：430展示标题：发展治疗 - 分子靶向药物和肿瘤生物学展示日期/时间：2025年6月2日下午1:30-4:30主要作者：R. JoshiBG-C9074摘要标题：BG-C9074（靶向B7-H4的ADC）用于治疗晚期实体瘤患者的首次人体研究：剂量递增阶段初步结果报告详情（美国中部夏令时间）：海报编号：348展示标题：发展治疗 - 分子靶向药物和肿瘤生物学展示日期/时间：2025年6月2日下午1:30-4:30主要作者：C.A. PerezBGB-A445（OX40激动剂）摘要标题：OX40激动剂BGB-A445联合或不联合抗PD-1单克隆抗体替雷利珠单抗用于治疗晚期NSCLC、HNSCC或NPC患者的1期临床研究报告详情（美国中部夏令时间）：海报编号：172展示标题：发展治疗 - 分子靶向药物和肿瘤生物学展示日期/时间：2025年6月2日下午1:30-4:30主要作者：M. Hee Hong摘要标题：OX40激动剂BGB-A445联合多西他赛或HPK1抑制剂BGB-15025用于治疗既往接受过抗PD-（L）1抗体治疗的NSCLC患者的2期临床研究报告详情：摘要编号：e14513在线摘要主要作者：T. Min Kim其他摘要临床试验多样性摘要标题：美国临床试验研究中心肺癌患者人口亚群入组情况报告详情（美国中部夏令时间）：海报编号：216展示标题：肺癌 - 非小细胞局部区域/小细胞/其他胸部癌症展示日期/时间：2025年5月31日下午1:30-4:30主要作者：C. Nigoghossian泽布替尼相关综合证据生成和健康经济学偏好调查摘要标题：滤泡性淋巴瘤患者、护理人员及医生的治疗偏好：全球自行选择实验研究报告详情（美国中部夏令时间）：海报编号：448展示标题：优质护理/健康服务研究展示日期/时间：2025年5月31日下午1:30-4:30主要作者：M. Smith匹配调整间接比较摘要标题：泽布替尼对比维奈克拉联合奥妥珠单抗固定疗程疗法用于治疗初治慢性淋巴细胞白血病患者的特别关注不良事件报告详情：摘要编号：e19028在线摘要主要作者：W. Aldairy摘要标题：泽布替尼持续给药对比维奈克拉联合奥妥珠单抗固定疗程疗法用于治疗初治慢性淋巴细胞白血病患者的有效性：匹配调整间接比较报告详情：摘要编号：e19027在线摘要主要作者：T. Munir摘要标题：泽布替尼对比阿可替尼联合维奈克拉固定疗程疗法用于慢性淋巴细胞白血病患者一线治疗的有效性比较：匹配调整间接比较报告详情：摘要编号：e91032在线摘要主要作者：T. Munir网络荟萃分析摘要标题：泽布替尼对比阿可替尼联合维奈克拉固定疗程疗法用于治疗初治慢性淋巴细胞白血病患者的有效性网络荟萃分析报告详情：摘要编号：e19031在线摘要主要作者：M. Shadman真实世界证据摘要标题：布鲁顿氏酪氨酸激酶抑制剂用于慢性淋巴细胞白血病患者一线治疗的真实世界有效性对比报告详情：摘要编号：e23264在线摘要主要作者：R. Jacobs摘要标题：评估不同人种/种族慢性淋巴细胞白血病患者在接受一线治疗时对靶向药物的摄取情况报告详情：摘要编号：e13741在线摘要主要作者：A.S. Kittai摘要标题：真实世界中布鲁顿氏酪氨酸激酶抑制剂在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中的使用情况及临床结果报告详情：摘要编号：e23271在线摘要主要作者：J. Hou摘要标题：美国社区肿瘤患者中既往接受过阿可替尼治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者在真实世界中接受泽布替尼治疗的模式报告详情：摘要编号：e23265在线摘要主要作者：J. Hou摘要标题：美国社区肿瘤患者中既往接受过布鲁顿氏酪氨酸激酶抑制剂治疗的套细胞淋巴瘤患者在真实世界中接受泽布替尼治疗的模式报告详情：摘要编号：e23270在线摘要主要作者：R. Choksi摘要标题：新诊断为慢性淋巴细胞白血病/小淋巴细胞淋巴瘤并接受过共价布鲁顿氏酪氨酸激酶抑制剂治疗的患者罹患高血压风险：真实世界研究报告详情：摘要编号：e23334在线摘要主要作者：A.K. Ali摘要标题：慢性淋巴细胞白血病患者接受布鲁顿氏酪氨酸激酶抑制剂一线治疗在真实世界中的治疗利用模式、治疗终止和医疗资源利用：年龄相关差异报告详情：摘要编号：e19033在线摘要主要作者：K. Yang摘要标题：接受维奈克拉联合奥妥珠单抗治疗的CLL/SLL患者和接受泽布替尼治疗的CLL/SLL患者发生严重感染情况对比：真实世界研究报告详情：摘要编号：e19026在线摘要主要作者：J. Colasurdo摘要标题：加州大学学术健康中心关于泽布替尼对比阿可替尼用于治疗CLL/SLL患者的真实世界治疗模式和结果报告详情：摘要编号：e23263在线摘要主要作者：A. Ayati有关我们在2025年ASCO年会展示内容的更多信息，请访问我们的会议网址：congress.beonemedicines.com。（上下滑动查看详情）关于百悦泽®（泽布替尼）百悦泽®是一款可以口服的布鲁顿氏酪氨酸激酶（BTK）小分子抑制剂，其设计主要通过优化生物利用度、半衰期和选择性，实现对BTK蛋白完全、持续的抑制。凭借与其他获批BTK抑制剂存在差异化的药代动力学特征，百悦泽®已被证明能在多个疾病相关组织中抑制恶性B细胞增殖。百悦泽®是全球获批适应症最广泛的BTK抑制剂。它同时也是唯一一款给药灵活，可每日一次或每日两次的BTK抑制剂。同时，百悦泽®也是目前唯一一个对另一种BTK抑制剂在复发/难治性慢性淋巴细胞白血病（CLL）或小淋巴细胞淋巴瘤（SLL）患者的3期研究中显示出优效性的BTK抑制剂。百悦泽®全球临床开发项目迄今已在超过30个国家和地区开展超过35项试验，入组约7,100例患者。百悦泽®已在全球超过75个市场获批，已有超过20万例患者接受了治疗。关于百泽安®（替雷利珠单抗）百泽安®（替雷利珠单抗）是一款具有独特设计的人源化免疫球蛋白G4（IgG4）抗程序性细胞死亡蛋白-1（PD-1）单克隆抗体，能够以高亲和力和特异性与PD-1结合；其设计最大限度地减少了与巨噬细胞中Fcγ受体的结合，帮助人体免疫细胞识别并杀伤肿瘤细胞。百泽安®是百济神州实体瘤产品组合的基石产品，已在多种肿瘤类型和疾病领域中显示出潜力。百泽安®临床开发项目迄今已在35个国家或地区开展70项试验，入组约14,000例受试者，包括21项注册可用研究。百泽安®已在46个市场获批，全球超过150万例患者接受了治疗。关于百济神州百济神州是一家全球肿瘤治疗创新公司，专注于为全世界的癌症患者研发创新抗肿瘤药物。通过强大的自主研发能力和外部战略合作，我们不断加速开发多元、创新的药物管线和产品组合，致力于为全球更多患者全面提升药物可及性和可负担性。在全球六大洲，我们拥有超过11,000人的团队。如需了解更多信息，请访问www.beigene.com.cn或关注“百济神州”微信公众号。前瞻性声明本新闻稿包含根据《1995年私人证券诉讼改革法案》（Private Securities Litigation Reform Act of 1995）以及其他联邦证券法律中定义的前瞻性声明，包括百济神州为全球尽可能多的患者提供创新药物的能力；百济神州肿瘤管线的深度和发展势头；以及在“关于百济神州”标题下提及的百济神州计划、承诺、愿望和目标。由于各种重要因素的影响，实际结果可能与前瞻性声明中的结果存在实质性差异。这些因素包括：百济神州证明其候选药物功效和安全性的能力；候选药物的临床结果可能不支持进一步开发或上市审批；药政部门的行动可能会影响到临床试验的启动、时间表和进展以及药物上市审批；百济神州的上市药物及候选药物（如能获批）获得商业成功的能力；百济神州获得和维护对其药物和技术的知识产权保护的能力；百济神州依赖第三方进行药物开发、生产、商业化和其他服务的情况；百济神州取得监管审批和商业化医药产品的有限经验，及其获得进一步的营运资金以完成候选药物开发及实现并保持盈利的能力；以及百济神州在最近季度报告的10-Q表格中“风险因素”章节里更全面讨论的各类风险；以及百济神州向美国证券交易委员会期后呈报中关于潜在风险、不确定性以及其他重要因素的讨论。本新闻稿中的所有信息仅及于新闻稿发布之日，除非法律要求，百济神州并无责任更新该等信息。— 左右滑动查看更多 —